Vera Therapeutics Income Statement (2020-2026) | VERA

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
20.97M13.44M26.76M27.00M27.61M27.80M44.26M44.31M44.43M44.45M54.46M54.82M55.03M63.56M63.77M63.82M63.89M71.27M71.73M72.06M
Operating items
Research & Development (Quarter)
3.56M-2.73M12.55M10.11M3.70M65.29M25.11M16.23M16.10M20.79M23.20M29.31M40.31M33.35M41.28M58.20M56.47M59.31M86.01M60.08M
Selling, General & Administrative (Quarter)
3.69M3.83M4.47M4.95M5.59M6.91M6.15M5.74M5.66M6.24M7.91M8.03M9.49M15.57M15.92M21.95M27.46M34.90M39.12M52.41M
Restructuring Costs (Quarter)
0.03M-0.12M
Other Operating Expenses (Quarter)
15.96M
Operating Expenses (Quarter)
7.25M16.59M17.02M15.06M25.24M33.58M31.26M21.97M21.76M27.03M31.11M37.34M49.80M48.91M57.19M80.14M83.93M94.21M125.13M112.49M
Operating Income (Quarter)
-7.25M-16.59M-17.02M-15.06M-25.24M-33.58M-31.26M-21.97M-21.76M-27.03M-31.11M-37.34M-49.80M-48.91M-57.19M-80.14M-83.93M-94.21M-125.13M-112.49M
EBIT (Quarter)
-7.25M-16.59M-17.02M-15.06M-25.24M-33.58M-31.26M-21.97M-21.76M-27.03M-31.11M-37.34M-49.80M-48.91M-57.19M-80.14M-83.93M-94.21M-125.13M-112.49M
Non-operating items
Non Operating Investment Income (Quarter)
-0.36M-0.25M-0.29M-0.26M-0.20M-0.06M-0.00M-0.03M-0.01M-0.00M-0.00M-0.01M
Interest & Investment Income (Quarter)
0.01M0.01M0.03M0.26M0.57M0.89M1.62M2.24M2.16M1.96M4.19M5.10M4.76M6.66M6.91M6.32M5.74M5.52M6.36M5.35M
Non Operating Income (Quarter)
-0.36M-0.26M-0.06M0.20M0.56M1.14M1.19M1.81M1.65M1.37M2.73M3.63M3.17M5.49M5.50M3.61M3.64M3.11M4.10M3.02M
Net income details
EBT (Quarter)
-7.25M-16.58M-17.65M-23.44M-33.32M-33.25M-30.51M-21.01M-25.26M-38.56M-33.50M-44.55M-52.99M-44.12M-61.94M-92.52M-81.42M-144.82M-288.25M-294.29M
Profit After Tax (Quarter)
-7.61M-16.85M-17.09M-14.85M-24.81M-32.38M-30.07M-20.16M-20.10M-25.40M-28.38M-33.71M-45.14M-43.42M-51.69M-76.53M-79.94M-91.10M-121.03M-109.72M
Income from Non-Controlling Interests (Quarter)
-7.61M15.76M17.10M-14.99M-24.81M146.18M29.85M
Income from Continuing Operations (Quarter)
-7.25M-16.58M-17.65M-23.44M-33.32M-33.25M-30.51M-21.01M-25.26M-38.56M-33.50M-44.55M-52.99M-44.12M-61.94M-92.52M-81.42M-144.82M-288.25M-294.29M
Consolidated Net Income (Quarter)
-7.25M-16.58M-17.65M-23.44M-33.32M-33.25M-30.51M-21.01M-25.26M-38.56M-33.50M-44.55M-52.99M-44.12M-61.94M-92.52M-81.42M-144.82M-288.25M-294.29M
Income towards Parent Company (Quarter)
-7.25M-16.58M-17.65M-23.44M-33.32M-33.25M-30.51M-21.01M-25.26M-38.56M-33.50M-44.55M-52.99M-44.12M-61.94M-92.52M-81.42M-144.82M-288.25M-294.29M
Net Income towards Common Stockholders (Quarter)
-7.25M-16.58M-17.65M-23.44M-33.32M-33.25M-30.51M-21.01M-25.26M-38.56M-33.50M-44.55M-52.99M-44.12M-61.94M-92.52M-81.42M-144.82M-288.25M-294.29M
Additional items
EPS (Basic) (Quarter)
-0.34-1.23-0.73-0.87-1.22-1.25-0.81-0.47-0.57-0.90-0.66-0.81-0.97-0.80-0.97-1.45-1.28-2.25-4.03-4.10
EPS (Diluted) (Quarter)
-0.34-1.23-0.73-0.87-1.22-1.25-0.81-0.47-0.57-0.90-0.66-0.81-0.97-0.80-0.97-1.45-1.28-2.25-4.03-4.10
Shares Outstanding (Quarter)
21.27M13.44M24.23M27.08M27.22M26.57M37.67M44.27M44.36M42.71M50.97M54.73M54.90M55.33M63.67M63.79M63.85M64.23M71.48M71.84M
Shares Outstanding (Diluted) (Quarter)
21.27M13.44M24.23M27.08M27.22M26.57M37.67M44.27M44.36M42.71M50.97M54.73M54.90M55.33M63.67M63.79M63.85M64.23M71.48M71.84M
EBITDA (Quarter)
-7.25M-16.59M-17.02M-15.06M-25.24M-33.58M-31.26M-21.97M-21.76M-27.03M-31.11M-37.34M-49.80M-48.91M-57.19M-80.14M-83.93M-94.21M-125.13M-112.49M
Interest Expenses (Quarter)
0.66M8.65M8.64M0.56M0.87M1.28M5.66M13.49M6.57M12.31M7.96M1.87M11.65M18.70M3.22M56.13M169.47M187.15M